Значения термина intestinal bd на английском

Conclusions: Infliximab was a well-tolerated and effective therapy for patients with moderate-to-severe intestinal BD.

Methods: We reviewed the medical records of 167 intestinal BD patients between March 1986 and April 2011.

We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment.

Conclusions: Our study demonstrates that a considerable number of patients experience disease relapse during follow-up despite a high-remission rate after medical treatment for intestinal BD.

During the follow-up period, cumulative recurrence rates for intestinal BD were 24.9% at 2 years and 43.0% at 5 years.

We collected clinical, demographic, and laboratory data for patients with 28 patients with intestinal BD who received at least 1 dose of infliximab.